Updated:
BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for...
BioMotiv
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.
General information
Firm type
Asset Manager
Year founded
2010
Location
Region
North America
Country
United States
City
Cleveland
Corporate office
Cleveland, OH, United States
Additional offices
Indianapolis, IN, United States
Principals
Baiju R. Shah
CEO
Michael D. Sosin
Managing Director
Sector focus
Frequently asked questions
How does BioMotiv source proprietary deal flow?
BioMotiv's primary deal flow comes through the Harrington Discovery Institute, an affiliated nonprofit that identifies and funds early-stage academic research with therapeutic potential. This exclusive pipeline gives BioMotiv access to discoveries from leading academic medical centers before they reach the broader venture market.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: